A study using an interferon-gamma (IFN-γ) release assay showed that NSCLC patients with low IFN-γ values of less than 10 or decreased IFN-γ levels by 3-6 weeks post treatment had more frequent pneumonitis from PD(L)1 inhibitors [121]. The gene discussed is IFNG; the disease is non-small cell lung carcinoma.